Just five months after Novo Nordisk launched Wegovy in India, the Danish company has partnered (PDF) with Emcure ...

Poviztra to be sold as 2.4 mg injectable; Emcure becomes first Indian firm with exclusive semaglutide distribution rights ...

Novo Nordisk India has joined forces with Emcure Pharmaceuticals to commercialize Poviztra, a weight-loss drug, in an effort ...

The collaboration gives Emcure exclusive rights to distribute and commercialise semaglutide for chronic weight management in India.

Emcure Pharma will be the exclusive distributor responsible for the commercialisation and marketing of Poviztra, the second brand of Wegovy.

The deal will help expand the availability and marketing of this weight-loss medicine, especially in areas where Novo Nordisk ...

Novo Nordisk and Emcure Pharma team up to bring Poviztra, a new weight loss injection, to India. Learn more about this latest ...

Our Bureau, Mumbai Monday, November 10, 2025, 12:45 Hrs [IST] ...

Novo Nordisk partners with Emcure to promote Wegovy, following Eli Lilly's recent collaboration with Cipla for tirzepatide in ...

The partnership comes just five months after Wegovy debuted in India, and signals Novo Nordisk’s intent to scale access ...

Biocon has announced that the U.S. Food and Drug Administration (US FDA) has concluded an inspection with two observations at ...

Middle-class Indians trying to lose weight are embracing drugs such as Mounjaro in a country that has been called the world’s diabetes capital.